Biogen vs Chick-fil-A

Side-by-side comparison of AI visibility scores, market position, and capabilities

Biogen leads in AI visibility (91 vs 82)

Biogen

LeaderHealthcare Tech

Enterprise

Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.

AI VisibilityBeta
Overall Score
A91
Category Rank
#129 of 290
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
93
Gemini
96

About

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.

Full profile

Chick-fil-A

LeaderConsumer Food & Beverage

Quick Service Restaurant

Largest US chicken QSR with $22B+ system sales; highest revenue per restaurant in fast food through exceptional service culture and tight franchise operator standards.

AI VisibilityBeta
Overall Score
A82
Category Rank
#2 of 6
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
84
Gemini
86

About

Chick-fil-A is the largest US quick-service chicken restaurant chain, generating over $22 billion in annual system-wide sales from approximately 3,000 locations — more revenue per restaurant than any other US fast food chain, including McDonald's. Founded in 1946 by S. Truett Cathy in Hapeville, Georgia, Chick-fil-A pioneered the chicken sandwich and built a brand synonymous with exceptional customer service, clean restaurants, and a distinctive cultural identity. The company is privately held by the Cathy family.

Full profile

AI Visibility Head-to-Head

91
Overall Score
82
#129
Category Rank
#2
84
AI Consensus
81
stable
Trend
stable
99
ChatGPT
92
93
Perplexity
84
96
Gemini
86
99
Claude
90
95
Grok
88

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.